|
|
|
|
This teleconference followed the release of the bio-era report "Biology and Borders: SARS AND THE NEW ECONOMICS OF BIOSECURITY." The teleconference discussed how global corporations, reflecting on their experience with the SARS outbreak, are reevaluating their exposure to biosecurity risks of all types, worldwide. The speakers, which included leaders from industry and the WHO, explored lessons learned from the SARS outbreak, and assessed forces that are driving the globalization of disease risk and the implications for risk management and prevention.
- What are the underlying forces behind trends in emerging infectious diseases in human and animal populations?
- What are the related economic consequences?
- What can governments and other stakeholders do to respond to emerging biosecurity threats?
- What roles and strategies can non-government stakeholders and networks pursue to mitigate and respond to these new challenges?
- How are leading companies across a wide variety of industries working to preempt these risks in their businesses?
- What tools are emerging to provide risk assessment, prediction, monitoring, mitigation and response capabilities?
- Biotechnology and health care executives
- Executives at companies with multi-national operations
- Global economists
- Biosecurity professionals
- Risk management and insurance professionals
- Federal, state and international agencies involved in homeland security, biotechnology and human and animal health
Stephen Aldrich, President and CEO, bio-era
Peter Daszak, PhD, Executive Director, Consortium for Conservation Medicine
Paul Epstein, MD, MPH, Associate Director, Center for Health and the Global Environment, Harvard Medical School
Ray Fabius, MD, Global Medical Director, General Electric
Rob Goldsmith, MD, Associate Medical Director, General Electric
David Heymann, MD, Director, Communicable Diseases Program, World Health Organization (WHO)
James Newcomb, Managing Director, Research, bio-era
Dr. Ray Fabius, Global Medical Leader for GE, and his colleague, Dr. Rob Goldsmith, Associate Global Medical Director, describe their company's response to SARS, beginning with the immediate and pragmatic challenges that emerged in managing personnel movements and international travel during the SARS crisis. GE developed a series of scenarios to consider how to respond to hypothetical situations that might occur in the workplace itself. Using these scenarios, the company developed response strategies covering...
Dr. David Heymann, Director of the Communicable Diseases Program at the World Health Organization , describes the WHO's approach to responding to infectious disease outbreaks, and the basis for the organization's advisories...
Click here to apply for a bio-era membership and to participate.
top
|
|
